Loading
Predilife Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 13 Jul 2026.
Predilife: what insiders have been doing
Predilife belongs to the Healthcare & Pharma sector. Filings by its managers are published through AMF. The last twelve months, up to 18 October 2026, brought 14 filings signed by 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 14 purchases totalling €14k, made by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €6,230 from Stéphane RAGUSA, disclosed on 29 April 2026, or 0.12% of market capitalisation. Those buying include 2 chief executives.
Compared with its exchange (316 companies, median 6 filings), a count of 14 filings is above the norm. Since 2021, the database holds 57 purchases and 6 sales by insiders of the company.
In the case of 10 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 13 July 2026, 96 days ago. Typically, a trade is published a median of 5 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
75
Thresholds
n/a
Buy Volume
€599,361
57 ops. · all time
Sell Volume
€710,200
6 ops. · all time
Who traded when
BuySaleStephane Ragusa13 buys
Stéphane Ragusa7 buys
SCI Faleche SAS1 sale
Since the insiders bought
- -50.7%Entry €1.80 · Close 13 Oct 2026 €0.89
- -71.2%Entry €3.09 · Close 13 Oct 2026 €0.89
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.89
Analyst consensus
Income statement
Revenue€836k
Gross profit€820k98% margin
EBITDA-€3.2M-383% margin
Net income-€3.9M-470.7% margin
Valuation
Beta0.28
Balance sheet & cash
Market cap€3.5M
Total debt€5.5M
Free Cash Flow-€2.6M
Profitability & ownership
ROA-95.5%
% insiders51.0%
% institutions0.0%
Last declaration on 13 July 2026
Declarations75 total
103 shares@ €2.000.0057% mcap5.4% of flowActionTrade rebelISIN FR00101699202026DD1126672
Canonical exit: 6 Oct 2026 (T+90)
3.34 shares@ €2.340.0002% mcap0.2% of flowActionEuronext Growth ParisISIN FR00101699202026DD1125646
Canonical exit: 30 Sept 2026 (T+90)
265 shares@ €2.310.017% mcap16.1% of flowActionEuronext Growth ParisISIN FR00101699202026DD1124853
Canonical exit: 29 Sept 2026 (T+90)
65 shares@ €2.400.0029% mcap100.0% of flowActionEuronext Growth ParisISIN FR00101699202026DD1123873
Canonical exit: 22 Sept 2026 (T+90)
10 shares@ €2.500.0005% mcap0.2% of flowActionEuronext Growth ParisISIN FR00101699202026DD1122772
Canonical exit: 16 Sept 2026 (T+90)
240 shares@ €2.660.012% mcap6.1% of flowActionEuronext Growth ParisISIN FR00101699202026DD1121514
Canonical exit: 8 Sept 2026 (T+90)
165 shares@ €2.450.0075% mcap10.7% of flowActionEuronext Growth ParisISIN FR00101699202026DD1120450
Canonical exit: 6 Sept 2026 (T+90)
1,000 shares@ €2.500.046% mcap65.9% of flowActionEuronext Growth ParisISIN FR00101699202026DD1119616
Canonical exit: 2 Sept 2026 (T+90)
235 shares@ €2.550.011% mcap5.7% of flowActionEuronext Growth ParisISIN FR00101699202026DD1119617
Canonical exit: 3 Sept 2026 (T+90)
310 shares@ €2.830.016% mcap8.3% of flowActionEuronext Growth ParisISIN FR00101699202026DD1119264
Canonical exit: 31 Aug 2026 (T+90)
780 shares@ €2.3540.034% mcap17.4% of flowActionEuronext Growth ParisISIN FR00101699202026DD1119265
Canonical exit: 1 Sept 2026 (T+90)
2,045 shares@ €3.04660.12% mcap59.1% of flowActionEuronext Growth ParisISIN FR00101699202026DD1110958
Canonical exit: 28 Jul 2026 (T+90)
110 shares@ €3.06730.0062% mcap3.2% of flowActionEuronext Growth ParisISIN FR00101699202026DD1109222
Canonical exit: 16 Jul 2026 (T+90)
20 shares@ €3.140.0012% mcap1.7% of flowActionEuronext Growth ParisISIN FR00101699202026DD1107455
Canonical exit: 9 Jul 2026 (T+90)
300 shares@ €4.800.1% of flowActionEuronext Growth ParisISIN FR00101699202025DD1038359
Canonical exit: 14 Aug 2025 (T+90)
500 shares@ €4.800.2% of flowActionEuronext Growth ParisISIN FR00101699202025DD1038297
Canonical exit: 14 Aug 2025 (T+90)
5,000 shares@ €3.80100.0% of flowActionEuronext Growth ParisISIN FR00101699202025DD1025542
2,000 shares@ €3.820.5% of flowActionEuronext Growth ParisISIN FR00101699202025DD1019754
2,000 shares@ €3.820.5% of flowActionEuronext Growth ParisISIN FR00101699202025DD1019341
400 shares@ €3.900.1% of flowActionEuronext Growth ParisISIN FR00101699202025DD1017947
Canonical exit: 30 Apr 2025 (T+90)
250 shares@ €4.000.1% of flowActionEuronext Growth ParisISIN FR00101699202025DD1017084
Canonical exit: 24 Apr 2025 (T+90)
500 shares@ €4.000.1% of flowActionEuronext Growth ParisISIN FR00101699202025DD1015061
Canonical exit: 10 Apr 2025 (T+90)
1,000 shares@ €3.800.3% of flowActionEuronext Growth ParisISIN FR00101699202025DD1013574
7,000 shares@ €3.801.9% of flowActionEuronext Growth ParisISIN FR00101699202024DD1012244
5,000 shares@ €4.201.5% of flowActionEuronext Growth ParisISIN FR00101699202024DD1007164
25 of 75 declarations
About Predilife
Predilife is a French company specializing in predictive medicine, listed on Euronext Growth Paris under ISIN code FR0010169920 and ticker ALPRE. Founded in 2004, the company was built around a clear mission: to make personalized prevention more accessible by combining artificial intelligence, Big Data and clinically validated medical methods. Its positioning sits at the intersection of healthcare, diagnostics and disease prevention, with a strong technology component.
The company’s history is rooted in a long research and development cycle. After roughly 14 years of R&D, Predilife obtained medical device certification and launched its first predictive health check-ups in France and internationally. Its flagship product, MammoRisk®, was developed to assess breast cancer risk using reference clinical databases and advanced statistical models. This product helped establish Predilife as a pioneer in personalized prevention, particularly in oncology.
Read moreShow less
Since 2021, the company has expanded its predictive portfolio to cover several other major conditions, including prostate cancer, melanoma, colorectal cancer, lung cancer and cardiovascular disease. This diversification strengthens the company’s value proposition: offering predictive tests that can identify significant health risks earlier, thereby improving prevention, screening and medical follow-up. Predilife also markets predictive check-ups for companies, helping HR teams and occupational health departments structure prevention initiatives for employees.
From a market standpoint, Predilife operates in a specialized niche within digital health and medical prevention. Its model addresses a market that is still relatively early-stage and not fully standardized, but one that offers meaningful growth potential as employers, healthcare providers and institutions seek more targeted screening solutions. The company highlights partnerships with major international databases and with recognized healthcare institutions in France and Europe. Its geographic footprint remains primarily centered on France, while its offering is designed for broader international expansion.
Notable features of Predilife include its science-driven model, which combines medical research, algorithms and individualized prevention. The company also emphasizes the economic rationale of its predictive check-ups, which are presented as significantly less expensive than traditional comprehensive medical screenings. Overall, Predilife stands out as an innovative healthcare company with a strong blend of scientific credibility, technological depth and scalable prevention-oriented solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
